When Should You Get a Mycoplasma/Ureaplasma Panel?

A mycoplasma/ureaplasma panel is a molecular diagnostic test, usually PCR-based, that screens for several tiny bacterial species in the urogenital tract at once. The panel typically targets organisms like Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma urealyticum, and Ureaplasma parvum. What makes the panel useful is also what makes it controversial: it can detect organisms that often live harmlessly in healthy people, meaning a positive result does not always mean you need treatment. Understanding which results matter and which do not is the single most important thing about this test.

What the Panel Actually Tests For

Most commercial mycoplasma/ureaplasma panels use nucleic acid amplification technology (NAAT), which detects the genetic material of the bacteria rather than trying to grow them in a lab. This matters because several of these organisms are extremely slow-growing or nearly impossible to culture by traditional methods. A multiplex PCR panel can identify multiple species from a single swab or urine sample with high sensitivity. One study comparing multiplex PCR with culture found PCR had a sensitivity of about 87% and specificity of 96%, while also catching infections that culture missed entirely.¹ For Ureaplasma species specifically, quantitative real-time PCR has shown sensitivities above 89% across different specimen types.²

The organisms on the panel are not all equally important. They fall into two broad categories: those with a clear link to disease and those whose clinical significance is uncertain or minimal. The species that get the most clinical attention is Mycoplasma genitalium, which is now recognized as a genuine sexually transmitted pathogen. The others, particularly Ureaplasma parvum and Mycoplasma hominis, are frequently found in healthy individuals without causing any problems. This distinction drives the entire debate about when and why to order the panel.

The Organisms and What They Do

Mycoplasma genitalium

M. genitalium is the organism on the panel with the strongest evidence behind it as a pathogen. In men, it is linked to acute and chronic urethritis, and European guidelines estimate it accounts for roughly 10 to 35% of non-chlamydial, non-gonococcal urethritis cases.³ In women, it has been associated with cervicitis, pelvic inflammatory disease, and possibly infertility, though the data in women have historically been more limited.⁴ One study from North India found tubal occlusion in a third of M. genitalium-positive infertility patients, suggesting the infection can cause real structural damage to reproductive organs if left untreated.⁵

M. genitalium can also infect sites beyond the genitals. A cohort study of men who have sex with men found that about 9% had rectal M. genitalium at enrollment, and rectal infections had a median duration of 42 weeks, with the majority being entirely asymptomatic.⁶ Pharyngeal infections were also detected, though less commonly. These extragenital infections are relevant because they can serve as unrecognized reservoirs for onward transmission.

Ureaplasma urealyticum and Ureaplasma parvum

These two Ureaplasma species are where things get murky. U. urealyticum has some evidence behind it as a cause of urethritis in men. Research has shown that higher bacterial loads of U. urealyticum correlate with symptomatic urethritis, while U. parvum loads show no such association.⁷ A case-control study found that U. urealyticum was more strongly linked to urethritis in men with fewer lifetime sexual partners, suggesting that repeated exposure may lead to some degree of adaptive immunity. U. parvum, by contrast, showed no positive association with urethritis in any subgroup.⁸

In women, neither Ureaplasma species has been convincingly tied to lower genital tract symptoms. A study comparing women with and without urogenital symptoms found no significant difference in detection rates of either U. parvum or U. urealyticum between the two groups.⁹ This is the core of the problem: these bacteria are incredibly common colonizers of the female genital tract, and detecting them on a panel result tells you very little about whether they are causing harm.

Mycoplasma hominis

M. hominis is another frequent colonizer of the genital tract, particularly in women. It has been associated with bacterial vaginosis (BV) and can be found alongside BV-associated organisms.¹⁰ Its role as an independent pathogen in women remains debated, much like the Ureaplasma species. It can, however, play a role in upper reproductive tract infections and pregnancy complications when it ascends from its usual habitat.

Why Experts Are Cautious About Routine Testing

This is the part of the panel conversation that often gets lost. A position statement from the European STI Guidelines Editorial Board put it bluntly: there is no evidence that routine testing and treatment for M. hominis, U. parvum, and U. urealyticum does more good than harm.¹¹ Asymptomatic carriage of these bacteria is common, and most colonized individuals never develop disease. The statement warned that widespread testing and subsequent antibiotic treatment could drive antimicrobial resistance not just in these organisms but across the broader microbial community, while also imposing unnecessary economic and psychological costs.

That psychological burden is real. A qualitative study of women diagnosed with U. urealyticum infection found that many experienced confusion, anxiety, shame, and self-doubt after receiving a positive result, even when the clinical significance of the finding was uncertain.¹² A positive panel result for an organism that may well be a normal commensal can generate real distress and lead to unnecessary treatment courses.

The situation is different for M. genitalium. Current clinical guidance recommends testing symptomatic patients for this organism and treating confirmed infections, while neither screening nor test-of-cure is recommended in asymptomatic individuals.¹³ So even for the one organism on the panel with clear pathogenic potential, screening healthy people without symptoms is not considered appropriate.

When a Panel Is Appropriate

The clearest indication for ordering a mycoplasma/ureaplasma panel is when someone has symptoms of urethritis, cervicitis, or pelvic inflammatory disease and standard testing for chlamydia and gonorrhea has come back negative. In that scenario, M. genitalium becomes a prime suspect, and the panel provides a straightforward way to check for it. For men with non-gonococcal urethritis that does not respond to first-line treatment, M. genitalium testing is particularly valuable because the treatment approach differs substantially from that used for chlamydia.

Some clinicians also find Ureaplasma results useful in the context of recurrent urethritis in men, especially when U. urealyticum is found in high quantities and other explanations have been excluded. But ordering the panel as part of a routine STI screen or a wellness check in someone without symptoms is where the evidence falls apart. You end up detecting organisms that are present in a large fraction of sexually active adults, creating diagnostic noise and anxiety without a clear path forward.

Specimen Types and Accuracy

The type of sample collected affects how well the test performs. For M. genitalium in women, vaginal swabs are clearly the most sensitive specimen. A head-to-head comparison found that vaginal swabs detected the organism in about 84 to 91% of infected women, while cervical swabs and urine each caught only around 53 to 65%.¹⁴ A newer commercial assay showed even higher sensitivity for vaginal swabs at about 97%, compared with 86% for urine.¹⁵

For men, first-void urine is typically the standard specimen. The practical takeaway is that if you are a woman being tested for M. genitalium and the test comes back negative on a urine sample, a false negative is plausible. A vaginal swab is the better option. Self-collected vaginal swabs are generally as accurate as clinician-collected ones for these molecular tests, which makes the process straightforward.

Pregnancy and Neonatal Risks

The context in which Ureaplasma and Mycoplasma species take on more serious significance is pregnancy. A systematic review and meta-analysis found that M. hominis was associated with nearly double the odds of preterm birth, and U. urealyticum and U. parvum showed similar associations with preterm birth and premature rupture of membranes.¹⁶ The association appeared stronger when bacterial vaginosis was also present. The review noted, however, that most of the underlying studies failed to adequately control for confounding factors, so these numbers should be interpreted with some caution.

Vertical transmission from mother to newborn is well-documented. Ureaplasma species can be isolated from the airways of newborns within minutes to hours after birth, and in very low birth weight infants (under 1,000 grams), the rate of vertical transmission from a colonized mother approaches 90%.¹⁷ Intrauterine or postnatal Ureaplasma infection has been identified as a risk factor for complications of extreme prematurity, including bronchopulmonary dysplasia and intraventricular hemorrhage.¹⁸ A smaller preliminary study in term newborns found that vertical transmission of Ureaplasma occurred in about 38% of colonized mother-child pairs, though these term infants did not develop respiratory disorders.¹⁹

The pregnancy picture illustrates why blanket statements about these organisms being “harmless commensals” are an oversimplification. They can be harmless in a healthy lower genital tract but potentially dangerous when they ascend to the upper reproductive tract or amniotic cavity. Whether routine screening in pregnancy would improve outcomes remains an open question, because large interventional trials have not been conducted.

Antibiotic Resistance and Treatment Strategy

Treating M. genitalium has become significantly more complicated over the past decade due to rising antibiotic resistance. A systematic review and meta-analysis found that the overall prevalence of mutations associated with macrolide (azithromycin) resistance in M. genitalium was about 36%, and this had climbed sharply over time, from roughly 10% before 2010 to over 50% by 2016-2017.²⁰ A similar trend was documented in Japan, where macrolide resistance mutations jumped from under 5% in the 2005-2009 period to over 42% in 2010-2017.²¹

This resistance problem has driven a shift toward resistance-guided therapy. The recommended approach for symptomatic M. genitalium infections now starts with a course of doxycycline to reduce the bacterial load, followed by azithromycin if the strain is macrolide-sensitive, or moxifloxacin if macrolide resistance mutations are detected.²² A UK sexual health center that adopted this resistance-guided approach reported that treatment failure dropped from 27% under empiric therapy to just 3% with guided treatment, a striking improvement.²³

Some advanced panel products now integrate macrolide resistance detection directly into the diagnostic test. This is genuinely useful because it lets clinicians choose the right antibiotic from the start rather than guessing, failing, and switching. If you are being tested for M. genitalium, it is worth asking whether the panel your provider is using includes resistance mutation testing.

Fluoroquinolone resistance is also emerging, though it remains less common than macrolide resistance. Research into specific mutations has found that some amino acid changes in the ParC protein confer high-level resistance to moxifloxacin, while others have minimal impact, which complicates the picture further.²⁴ For cases where both macrolide and fluoroquinolone resistance is present, treatment options shrink dramatically. Early laboratory work on the novel antibiotic lefamulin has shown strong activity against M. genitalium isolates, including highly resistant strains, which offers some hope for the future of multidrug-resistant infections.

For U. urealyticum and M. hominis, the resistance landscape looks different. Tetracyclines like doxycycline remain highly effective against both, with susceptibility rates above 94% for U. urealyticum and 100% for M. hominis in one large surveillance study. But M. hominis is intrinsically resistant to macrolides like azithromycin, with over 95% of isolates showing resistance, while U. urealyticum tends to respond to macrolides.²⁵ This is a practical reason why knowing exactly which species the panel has identified matters for treatment decisions.

Test of Cure and Follow-Up

If you are treated for M. genitalium, a follow-up test to confirm the infection has cleared is generally recommended, but timing matters. After azithromycin treatment, PCR tests can become negative fairly quickly, but macrolide-resistant strains may re-emerge after initially negative results. Research suggests that a test of cure should not be performed earlier than three to four weeks after completing treatment, because testing too soon can produce misleading negatives.²⁶ For Ureaplasma species, test-of-cure practices are less standardized, partly because the clinical significance of persistent colonization is not well defined.

The Overtesting Problem in Practice

In some parts of the world, particularly in private or direct-to-consumer testing settings, mycoplasma/ureaplasma panels have become a popular add-on to routine sexual health checkups. The panels are marketed as comprehensive, and the appeal of “testing for everything” is understandable. But the consequences of casting a wide net can be counterproductive. A person who tests positive for U. parvum, which is arguably just part of a normal genital microbiome, may end up on antibiotics they did not need. Those antibiotics carry their own risks of side effects and contribute to the broader problem of antimicrobial resistance. The European position statement specifically flagged this dynamic, noting that extensive testing and treatment of these bacteria in some settings may drive resistance not only in the targeted organisms but across the entire microbiota.²⁷

The most sensible use of a mycoplasma/ureaplasma panel is targeted rather than routine: test symptomatic patients who have already been evaluated for the usual suspects like chlamydia and gonorrhea, and focus clinical attention on the results that have clear pathogenic significance. A positive M. genitalium result in someone with urethritis or cervicitis warrants treatment. A positive U. parvum result in an asymptomatic person warrants a conversation about what the finding means, which in most cases is very little.